Biomarkers for personalised treatment in psychiatric diseases

Expert Opinion on Medical Diagnostics

Volumn 7, Issue 5, 2013, Pages 417-422

  Bagdy, Gyorgy ^a,b   Juhasz, Gabriella ^a,b,c  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Biomarkers; Gene environment interaction; Gene gene interaction; Heritability; Intermediate phenotype; Psychiatric disorders

Indexed keywords

BAPINEUZUMAB; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; ANXIETY DISORDER; ARTICLE; AUTISM; COMORBIDITY; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EPISTASIS; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC RISK; GENOMICS; HUMAN; MAJOR DEPRESSION; MENTAL DISEASE; PHENOTYPE; PSYCHIATRIC TREATMENT; RISK FACTOR; SCHIZOPHRENIA; GENETICS; MENTAL DISORDERS; PERSONALIZED MEDICINE; PROCEDURES;

BIOLOGICAL MARKERS; HUMANS; INDIVIDUALIZED MEDICINE; MENTAL DISORDERS; PHENOTYPE;

EID: 84883182615     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2013.821979     Document Type: Article

References (22)

1. Sullivan PF, Daly MJ, ODonovan M. Genetic architectures of psychiatric disorders: The emerging picture and its implications. Nat Rev Genet 2012;13(8):537-51
2. Thomas D. Gene-environment-wide association studies: Emerging approaches. Nat Rev Genet 2010;11(4):259-72
3. Smoller JW, Craddock N, Kendler K, et al. Identification of risk loci with shared effects on five major psychiatric disorders: A genome-wide analysis. Lancet 2013;381(9875):1371-9
4. Lazary J, Lazary A, Gonda X, et al. New evidence for the association of the serotonin transporter gene (SLC6A4) haplotypes, threatening life events, and depressive phenotype. Biol Psychiatry 2008;64(6):498-504
5. Karg K, Burmeister M, Shedden K, Sen S. The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: Evidence of genetic moderation. Arch Gen Psychiatry 2011;68(5):444-54
6. Murphy DL, Uhl GR, Holmes A, et al. Experimental gene interaction studies with SERT mutant mice as models for human polygenic and epistatic traits and disorders. Genes Brain Behav 2003;2(6):350-64
7. Pezawas L, Meyer-Lindenberg A, Goldman AL, et al. Evidence of biologic epistasis between BDNF and SLC6A4 and implications for depression. Mol Psychiatry 2008;13(7):709-16
8. Lazary J, Lazary A, Gonda X, et al. Promoter variants of the cannabinoid receptor 1 gene (CNR1) in interaction with 5-HTTLPR affect the anxious phenotype. American journal of medical genetics Part B. Neuropsychiat Genet 2009;150B(8):1118-27
9. Lazary J, Juhasz G, Hunyady L, Bagdy G. Personalized medicine can pave the way for the safe use of CB(1) receptor antagonists. Trends Pharmacol Sci 2011;32(5):270-80
10. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69(3):89-95
11. Lenzenweger MF. Endophenotype, intermediate phenotype, biomarker: Definitions, concept comparisons, clarifications. Depress Anxiety 2013;30(3):185-9
12. Meyer-Lindenberg A, Weinberger DR. Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat Rev Neurosci 2006;7(10):818-27
13. Walters JT, Owen MJ. Endophenotypes in psychiatric genetics. Mol Psychiatry 2007;12(10):886-90
14. Juhasz G, Dunham JS, McKie S, et al. The CREB1-BDNF-NTRK2 pathway in depression: Multiple genecognition- environment interactions. Biol Psychiatry 2011;69(8):762-71
15. Bagdy G, Juhasz G, Gonda X. A new clinical evidence-based gene-environment interaction model of depression. Neuropsychopharmacol Hung 2012;14(4):213-20
16. Sun H, Kennedy PJ, Nestler EJ. Epigenetics of the depressed brain: Role of histone acetylation and methylation. Neuropsychopharmacology 2013;38(1):124-37
17. Arnone D, McKie S, Elliott R, et al. Increased amygdala responses to sad but not fearful faces in major depression: Relation to mood state and pharmacological treatment. Am J Psychiatry 2012;169(8):841-50
18. Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: A network-based approach to human disease. Nat Rev Genet 2011;12(1):56-68
19. Cline BH, Steinbusch HW, Malin D, et al. The neuronal insulin sensitizer dicholine succinate reduces stress-induced depressive traits and memory deficit: Possible role of insulin-like growth factor 2. BMC Neurosci 2012;13:110
20. Uher R, Tansey KE, Malki K, Perlis RH. Biomarkers predicting treatment outcome in depression: What is clinically significant? Pharmacogenomics 2012;13(2):233-40
21. Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimers disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9(4):363-72
22. Uher R. The role of genetic variation in the causation of mental illness: An evolution-informed framework. Mol Psychiatry 2009;14(12):1072-82